Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me)
In addition, different therapeutic windows, treatment durations, and dosing regimens should be investigated to better clarify the influence of sex and developmental timing on treatment efficacy in ASD models
67.6% women) who were randomly assigned to receive subcutaneous cagrilintide/semaglutide (CagriSema, Novo Nordisk), semaglutide 2.4 mg alone (Wegovy, Novo Nordisk), cagrilintide 2.4 mg alone or placebo
Most patients qualify for therapy if they have a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea